Implant Sciences Announces another Significant ECAC Win
Implant Sciences Corporation (OTCQB: IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, today reported that the Company has received an order for 75 QS-B220 explosives trace detection systems in the Netherlands. The systems are expected to be delivered in the Company's fourth fiscal quarter and will be used for screening passengers and baggage in an airport environment.
"The customer tested multiple ETD systems before making their selection. After weeks of testing and thousands of samples, the customer informed us that the QS-B220 had the lowest false alarm rate out of all of the tested systems. When screening millions of passengers per year, false alarms carry a tremendous monetary cost and are disruptive to security operations and passenger experience," stated Dr. Darryl Jones, Vice President of Global Sales and Marketing. "The selection of Implant Sciences by this customer, reinforced by the recent U.S. aviation procurement, demonstrates that the QS-B220 is well suited to deliver superior results for high-throughput airports, where false alarm rates matter the most."
Special Mission Aircraft Market - Global Forecast to 2020
"This is a very prestigious win for our QS-B220. Implant Sciences is honored to enhance aviation security and integrate our product into an industry-leading passenger checkpoint experience," stated Richard Nelson, General Manager, EMEA for Implant Sciences.
About the QS-B220 Desktop Explosives and Drugs Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives as well as illicit drugs. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
Source : Implant Sciences Corporation - view original press release
May 24 - 25, 2017 - London, United Kingdom
Jun 5 - 8, 2017 - Washington, United States